Brixmor Property Group Inc.
$14.08B- Market cap
- $8.95B
- Debt
- +$5.49B
- Cash
- −$355.71M
Capital structure 62% equity / 38% debt · EV / Revenue 10.27x · EV / EBITDA 21.90x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BRX stock price at discount vs CRSP $29.15 current versus $6.87K implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CRSP's multiple
Implied fair value · at BRX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BRX FY 2025 (ended Dec 31, 2025) · CRSP FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 62% equity / 38% debt · EV / Revenue 10.27x · EV / EBITDA 21.90x
Capital structure 96% equity / 4% debt · EV / Revenue 1030.76x
BRX carries the larger enterprise value at $14.08B against $3.62B; BRX trades on the lower EV / Revenue multiple (10.27x vs 1030.76x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Brixmor Property Group Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
CRISPR THERAPEUTICS AG · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.83x
0.10x
Net debt / EBITDA
Leverage against operating earnings
7.99x
3.18x
Cash and equivalents
Liquid reserves on the balance sheet
$355.71M
$1.98B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$5.49B
$197.39M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.